Artificial Intelligence in Life Sciences Market Report 2026

The artificial intelligence in life sciences market size has grown exponentially in recent years. It will grow from $3.59 billion in 2025 to $4.44 billion in 2026 at a compound annual growth rate (CAGR) of 23.6%. The growth in the historic period can be attributed to increasing complexity of biological datasets, expansion of genomics research, rising adoption of digital lab technologies, early integration of ai in biotechnology research, growing demand for faster research cycles.

The artificial intelligence in life sciences market size is expected to see exponential growth in the next few years. It will grow to $10.43 billion in 2030 at a compound annual growth rate (CAGR) of 23.8%. The growth in the forecast period can be attributed to increasing investments in personalized medicine, rising deployment of ai-enabled laboratory automation, expansion of cloud-based life science platforms, growing collaboration between tech and life science firms, increasing regulatory acceptance of ai-driven insights. Major trends in the forecast period include increasing integration of ai across life science workflows, rising adoption of AI-driven data analytics platforms, growing use of automation in laboratory operations, expansion of AI-based precision medicine applications, enhanced focus on accelerating research outcomes.

The growing interest in real-time remote patient monitoring (RPM) systems is anticipated to drive the expansion of artificial intelligence in the life sciences market going forward. A remote patient monitoring system is a technology-based healthcare solution designed to track patients' health outside conventional healthcare environments. AI in life sciences plays a crucial role in remote patient monitoring by delivering continuous, personalized, and data-driven insights that support proactive healthcare management. For example, in April 2025, the Peterson Center on Healthcare, a US-based non-profit organization, reported that spending on remote therapeutic monitoring (RTM) in Traditional Medicare increased from $2.2 million in 2022 to $10.4 million in 2023. Additionally, in 2023, 451,000 patients in Traditional Medicare utilized RPM services. Thus, the rising interest in real-time remote patient monitoring (RPM) systems is fueling the growth of artificial intelligence in the life sciences market.

Major companies in the artificial intelligence in the life sciences market are concentrating on innovative solutions with technological advancements, such as drug discovery software, to maintain their market position. Drug discovery software is a type of computer program and application designed to support pharmaceutical and biotechnology researchers in discovering new drugs. For example, in December 2023, Merck, a Germany-based science and technology company, launched AIDDISON, a pioneering drug discovery software. As the first of its kind, it links virtual molecule design with real-world manufacturability, utilizing generative AI, machine learning, and computer-aided drug design. AIDDISON effectively identifies drug candidates from a vast range of possibilities, taking into account essential properties like non-toxicity and solubility. Its capability to connect virtual molecule design with real-world manufacturability is a significant application of artificial intelligence in the life sciences industry.

In June 2023, Varix, a US-based pharmaceutical commercial operations company, acquired Start-up.ai for an undisclosed amount. The acquisition of Start-up.ai by Varix aims to strengthen its capabilities in artificial intelligence (AI) and machine learning (ML) within the pharmaceutical commercial operations sector. Start-up.ai, an Israel-based AI-driven commercial optimization platform provider, will help enhance Varix’s life science AI capabilities.

Major companies operating in the artificial intelligence in life sciences market are Google LLC, Microsoft Corporation, Intel Corporation, IBM Corporation, Medtronic PLC, Nvidia Corporation, Novo Nordisk A/S, Siemens Healthineers AG, Philips Healthcare, Babylon Healthcare Services Ltd., Komodo Health Inc., Modernizing Medicine Inc., Viz.ai Inc., Butterfly Network Inc., Augmedix, AiCure LLC, HealthTap Inc., Welltok Inc., Enlitic Inc., PathAI Inc., Nano-X Imaging Ltd., Berg LLC, Insitro, Sense.ly Inc., Subtle Medical Inc., Medasense Biometrics Limited, Immunai, Atomwise Inc., Freenome Holdings Inc., CloudMedX Inc.

North America was the largest region in the Artificial Intelligence In Life Sciences market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence in life sciences market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence in life sciences market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the artificial intelligence in life sciences market by increasing costs of imported laboratory equipment, robotic systems, sensors, high-performance computing hardware, and data infrastructure components. Research institutions and biotechnology companies in North America and Europe are most affected due to reliance on imported advanced equipment, while Asia-Pacific faces cost pressures on research infrastructure expansion. These tariffs are raising capital expenditures and slowing modernization efforts. However, they are also encouraging domestic equipment manufacturing, regional R&D investments, and long-term development of software-centric AI life science solutions.

The artificial intelligence in life sciences market research report is one of a series of new reports that provides artificial intelligence in life sciences market statistics, including artificial intelligence in life sciences industry global market size, regional shares, competitors with a artificial intelligence in life sciences market share, detailed artificial intelligence in life sciences market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence in life sciences industry. This artificial intelligence in life sciences market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Artificial intelligence (AI) in life sciences involves the use of AI technologies and techniques across different areas within the life sciences sector. The adoption of AI in life sciences is designed to streamline and accelerate processes, enhance decision-making, and extract meaningful insights from complex data sets.

The primary offerings of artificial intelligence in life sciences include software, hardware, and services. The software leverages AI algorithms to analyze extensive chemical databases, predicting the potential of specific molecules to bind with target receptors, thereby speeding up the drug discovery process. These solutions are implemented through on-premises and cloud-based platforms and are applied in various areas such as drug discovery, medical diagnosis, biotechnology, clinical trials, precision and personalized medicine, and patient monitoring.

The artificial intelligence (AI) in the life sciences market consists of revenues earned by entities by private analytics, AI-driven clinical trial services, and real-world evidence services. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI) in the life sciences market also consists of sales of high-performance computing (HPC) clusters, edge computing devices, and IoT devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.